Integra Lifesciences Holdings Corp  

(Public, NASDAQ:IART)   Watch this stock  
Find more results for IART
-1.07 (-1.39%)
Dec 2 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 75.41 - 77.86
52 week 54.75 - 88.86
Open 76.82
Vol / Avg. 608,917.00/699,228.00
Mkt cap 2.69B
P/E 48.74
Div/yield     -
EPS 1.55
Shares 37.39M
Beta 0.75
Inst. own 92%
Feb 23, 2017
Q4 2016 Integra LifeSciences Holdings Corp Earnings Release (Estimated) - 9:30AM EST - Add to calendar
Dec 21, 2016
Integra LifeSciences Holdings Corp Extraordinary Shareholders Meeting - 9:00AM EST - Add to calendar
Nov 29, 2016
Integra LifeSciences Holdings Corp at Piper Jaffray Healthcare Conference
Oct 27, 2016
Q3 2016 Integra LifeSciences Holdings Corp Earnings Call - Webcast
Oct 27, 2016
Q3 2016 Integra LifeSciences Holdings Corp Earnings Release
Sep 13, 2016
Integra LifeSciences Holdings Corp at Morgan Stanley Global Healthcare Conference
Sep 7, 2016
Integra LifeSciences Holdings Corp at Wells Fargo Securities Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '16) 2015
Net profit margin 8.05% 0.78%
Operating margin 12.02% 9.18%
EBITD margin - 21.08%
Return on average assets 4.44% 0.41%
Return on average equity 9.99% 0.94%
Employees 3,500 -
CDP Score - -


311 Enterprise Dr
PLAINSBORO, NJ 08536-3344
United States - Map
+1-609-2750500 (Phone)
+1-609-2755363 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing and marketing of surgical implants and medical instruments. Its products are used in neurosurgery, extremity reconstruction, orthopedics and general surgery. Its segments include Specialty Surgical Solutions, which offers products, including specialty surgical instrumentation for a range of specialties. Its product category includes products and solutions for dural repair, precision tools and instruments, tissue ablation and neuro critical care, including product portfolios used in neurosurgery operation suites and critical care units, and Orthopedics and Tissue Technologies, which offers products of a combination of differentiated regenerative technology products for soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement hardware products for both upper extremities and lower extremities.

Officers and directors

Stuart M. Essig Ph.D. Independent Chairman of the Board
Age: 54
Bio & Compensation  - Reuters
Peter J. Arduini President, Chief Executive Officer, Director
Age: 51
Bio & Compensation  - Reuters
Glenn G. Coleman Chief Financial Officer, Corporate Vice President
Age: 48
Bio & Compensation  - Reuters
Lisa Evoli Corporate Vice President, Chief Human Resources Officer
Age: 46
Bio & Compensation  - Reuters
Kenneth Burhop Ph.D. Chief Scientific Officer, Corporate Vice President
Age: 62
Bio & Compensation  - Reuters
John Mooradian Corporate Vice President - Global Operations and Supply Chain
Age: 60
Bio & Compensation  - Reuters
Richard D. Gorelick Corporate Vice President, General Counsel, Administration, Secretary
Age: 55
Bio & Compensation  - Reuters
Robert T. Davis Jr. Corporate Vice President, President - Specialty Surgical Solutions
Age: 57
Bio & Compensation  - Reuters
Judith E. O'Grady R.N. Corporate Vice President - Global Regulatory Affairs
Age: 65
Bio & Compensation  - Reuters
Daniel L. Reuvers Corporate Vice President, President - International
Age: 53
Bio & Compensation  - Reuters